Global Neglected Tropical Diseases Treatment Market Up

  • Growing government support and rise in special designation from the regulatory authorities is driving the market growth.
  • Huge financial support to the researchers for developing novel intervention is boosting market growth.
  • Low healthcare budget in some developing countries is hampering the market growth.

Global neglected tropical diseases treatment market is market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Recent approval, launches of novel treatment  and high demand of disease-specific therapies are key factors fueling market growth.

Key Market Players

A few of the major competitors currently working in the global neglected tropical diseases treatment market are Emergent BioSolutions Inc, Moderna, Valneva SE, Johnson & Johnson Services, Inc, DAIICHI SANKYO COMPANY, LIMITED,  Insud Pharma group, Humanigen, Inc, Savant HWP, Inc, Bayer AG, Eisai Co., Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Themis Bioscience GmbH, Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Veru Inc, Regeneron Pharmaceuticals, Inc, Swedish Orphan Biovitrum AB,  and others

Children who have received treatment for neglected tropical disease. From WHO www.who.int

Market Definition

Neglected tropical diseases is defined as diverse and heterogeneous group of communicable diseases that prevails in the tropical and subtropical conditions with approximately 149 countries

According to the statistics published by the National Organization for Rare Disorders, Inc, familial Mediterranean fever is more prevalent in the south-eastern Mediterranean area with the estimated annual prevalence of (1/200-1/1000). Growing government support and rise in special designation from the regulatory authorities is driving the market growth.

Market Drivers

  • Growing prevalence of infections in tropical and subtropical origin including North African, Jewish, Arab, Armenian, Turkish, Greek or Italian ancestry is driving the growth of this market.
  • Huge financial support to the researchers for developing novel intervention is boosting market growth.
  • High demand of disease specific novel treatment can also act as a market driver
  • Increase in special designation from the regulatory authority is propelling the growth of this market

Market Restraints

  • Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market.
  • Low healthcare budget in some developing countries is hampering the market growth.

Segmentation

  • By Disease Type, Mediterranean Fever, Ebola Virus Infection, Chagas Disease, Zika Virus Infection, Chikungunya and Others.
  • By Treatment Type, Drugs, Analgesics, Antipyretics, Antibiotics, Others, Vaccine, Dengvaxia, Mosquirix and Others.
  • By Route of Administration, Oral and Injected.
  • By End Users, Hospitals, Homecare, Specialty Clinics and Others.
  • By Distribution Channel, Hospital Pharmacies, Retail Pharmacies and Others.

Get Sample Analysis of Global Market Information

Get TOC of Full Report

WHO photo of girl holding oral disease treatment pill. www.who.int/neglected_diseases/en/

Key Developments in the Market

In March 2017, DAIICHI SANKYO COMPANY, LIMITED entered into research collaboration with Drugs for Neglected Diseases initiative (DNDi) to develop the drugs for Chagas disease and leishmaniasis. This collaboration will improve the access to disease specific novel treatment for neglected tropical diseases including Chagas disease and leishmaniasis.

In September 2016, Novartis AG has received three simultaneous approvals for the expanded use of Ilaris (canakinumab), an interleukin-1β blocker for the treatment of three distinct types of Periodic Fever Syndromes including Tumor Necrosis Factor-Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF). This drug has also received Breakthrough Therapy designation from the FDA. The expanded approval of Ilaris represents transformative treatments to patients with a high medical need.

Competitive Analysis

Global neglected tropical diseases treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global neglected tropical diseases treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Only $1/click

Submit Your Ad Here

Rashi Pande

About Us Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. 
https://www.databridgemarketresearch.com/

Leave a Reply